Last reviewed · How we verify
Licensed Influenza Vaccine 1
Licensed Influenza Vaccine 1 is a Biologic drug developed by BioNTech SE. It is currently in Phase 1 development.
At a glance
| Generic name | Licensed Influenza Vaccine 1 |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Irritability
- Pain
- Drowsiness
- Redness
- Loss of appetite
- Swelling
- Fever
- Increase in limb circumference
- Upper respiratory tract infection
- COVID-19
- Pyrexia
- Otitis media
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (PHASE1)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Licensed Influenza Vaccine 1 CI brief — competitive landscape report
- Licensed Influenza Vaccine 1 updates RSS · CI watch RSS
- BioNTech SE portfolio CI
Frequently asked questions about Licensed Influenza Vaccine 1
What is Licensed Influenza Vaccine 1?
Licensed Influenza Vaccine 1 is a Biologic drug developed by BioNTech SE.
Who makes Licensed Influenza Vaccine 1?
Licensed Influenza Vaccine 1 is developed by BioNTech SE (see full BioNTech SE pipeline at /company/biontech-se).
What development phase is Licensed Influenza Vaccine 1 in?
Licensed Influenza Vaccine 1 is in Phase 1.
What are the side effects of Licensed Influenza Vaccine 1?
Common side effects of Licensed Influenza Vaccine 1 include Irritability, Pain, Drowsiness, Redness, Loss of appetite, Swelling.
Related
- Manufacturer: BioNTech SE — full pipeline
- Compare: Licensed Influenza Vaccine 1 vs similar drugs
- Pricing: Licensed Influenza Vaccine 1 cost, discount & access